Elucid PlaqueIQ
Elucid Bioimaging, Inc. · Decision date Sep 18, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for Elucid PlaqueIQ, a Class II radiological image-processing system under 21 CFR 892.2050, product code LLZ, submitted by Elucid Bioimaging, Inc. of Boston. The decision date is September 18, 2026; the public 510(k) database lists a June 3, 2026 receipt date, while the clearance letter cites a device dated August 20, 2026 and received August 21, 2026. SESE is a 510(k) clearance, not a PMA approval.
The summary describes a cloud-based application in which Elucid analysts generate segmentations and plaque quantification from previously acquired CT angiography for physician review, contrasted with the on-premises predicate Autoplaque add-on ORS Visual (K122429); K241524 is listed as a reference device. The summary reports reader-comparison stenosis performance figures, but the source does not establish independent clinical validation, and the TPLC excerpt's mention of a parameter calculation error is not explained in the provided material.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 18, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261855
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Elucid Bioimaging, Inc.
- Product code
- LLZ
- Decision code
- SESE
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Image Processing, Radiological.
- Applicant
- Elucid Bioimaging, Inc.
- Product code
- LLZ
- FDA device class
- 2
FDA decision timeline
K261855 received
Application receipt date recorded by FDA.
K261855 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LLZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
3D Anatomical ModelK262132 | The Jacobs Institute | 510(k) clearance | Nov 5, 2026 | FDA |
LiLi DICOM Viewer (LiLi )K260454 | Elevate Imaging, Inc. | 510(k) clearance | Nov 4, 2026 | FDA |
| Canon Medical Informatics, Inc. | 510(k) clearance | Oct 29, 2026 | FDA | |
MIM KineticIDK261763 | Mim Software, Inc. | 510(k) clearance | Oct 26, 2026 | FDA |
PV-iCurve ProK261531 | Perception Vision Medical Technology Co., Ltd. | 510(k) clearance | Oct 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Elucid Bioimaging, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Boston, MA
Sources and methodology
- Original FDA record: K261855
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


